Pharma
Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.